TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8874180

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HDAC) at 2 g/m2 intravenously every 12 hours for 12 doses plus daunorubicin (DNR) at 45 mg/m2/d intravenously for 3 days
Number of subjects: 665

Group type: COMPARATOR
Intervention: Standard-dose cytarabine (SDAC) 200 mg/m2/d for 7 days by continuous infusion plus daunorubicin (DNR) at 45 mg/m2/d intravenously for 3 days
Number of subjects: 665
Study: 1997047

Group type: EXPERIMENTAL
Intervention: Midazolam and Thiopentone (combination)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Thiopentone alone
Number of subjects: 300

Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 300
Study: 6647201

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Discontinuation of lipophilic beta-blockers
Number of subjects: 17
Study: 31254337

Group type: EXPERIMENTAL
Intervention: Higher ratings on technical skills
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Higher ratings on technical skills for specialists
Number of subjects: 600
Study: 29898842

Group type: EXPERIMENTAL
Intervention: ARNI prescription post-guideline publication
Number of subjects: 7200

Group type: COMPARATOR
Intervention: ARNI prescription pre-guideline publication
Number of subjects: 7200

Group type: EXPERIMENTAL
Intervention: ARNI use after guideline publication
Number of subjects: 7200
Study: 26903712

Group type: EXPERIMENTAL
Intervention: 12-week combined endurance and resistance exercise program
Number of subjects: 0
Study: 25062420

Group type: EXPERIMENTAL
Intervention: Lifestyle + Drug
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Drug
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Lifestyle
Number of subjects: 1112

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 1112
Study: 22693148

Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic exercise
Number of subjects: 26

Group type: COMPARATOR
Intervention: Resistance training alone
Number of subjects: 26
Study: 19961574

Group type: EXPERIMENTAL
Intervention: Sodium ibuprofen (2x256 mg tablets)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ibuprofen/poloxamer (2x200 mg tablets + 60 mg poloxamer 407)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard ibuprofen (2x200 mg tablets)
Number of subjects: 22
Study: 17574819

Group type: EXPERIMENTAL
Intervention: Soy-based low-calorie diet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional low-calorie diet
Number of subjects: 30
Study: 15465544

Group type: EXPERIMENTAL
Intervention: 1-piece Acrysof IOL
Number of subjects: 52

Group type: COMPARATOR
Intervention: 3-piece Acrysof IOL
Number of subjects: 52
Study: 11162323

Group type: EXPERIMENTAL
Intervention: Interactive expert system intervention
Number of subjects: 4653

Group type: EXPERIMENTAL
Intervention: Expert system intervention plus counselor calls
Number of subjects: 4653

Group type: EXPERIMENTAL
Intervention: Expert system intervention plus stimulus control computer
Number of subjects: 4653

Group type: COMPARATOR
Intervention: Assessment only condition
Number of subjects: 4653
Study: 9549651

Group type: EXPERIMENTAL
Intervention: Felbamate (3,000 or 3,600 mg/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Felbamate (3,000 or 3,600 mg/day) with erythromycin (333 mg three times daily for 10 days)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Felbamate with erythromycin
Number of subjects: 2
Study: 8036686

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) treatment
Number of subjects: 193
Study: 2564058

Group type: EXPERIMENTAL
Intervention: Edwards‐Duromedics valve
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Medtronic‐Hall valve
Number of subjects: 434

Group type: COMPARATOR
Intervention: Björk‐Shiley valve
Number of subjects: 434
Study: 30362964

Group type: EXPERIMENTAL
Intervention: Radiomic signature (six-feature radiomic signature)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Nomogram for individualized survival prediction
Number of subjects: 233
Study: 27646142

Group type: EXPERIMENTAL
Intervention: Cemented tapered femoral stem
Number of subjects: 140

Group type: COMPARATOR
Intervention: Uncemented tapered hydroxyapatite‐coated femoral stem
Number of subjects: 140
Study: 25672274

Group type: EXPERIMENTAL
Intervention: Formula enriched with eicosapentaenoic acid (EPA), gamma-linolenic acid (GLA) and antioxidants
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 120
Study: 23652752

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate 0.4% ointment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lidocaine chlorohydrate 2.5% gel
Number of subjects: 41
Study: 20660806

Group type: EXPERIMENTAL
Intervention: REG1 (RB006)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RB006 with partial reversal (RB007)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RB007 (complete reversal)
Number of subjects: 24
Study: 18086170

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 17168431

Group type: EXPERIMENTAL
Intervention: Oral glutamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 14609909

Group type: EXPERIMENTAL
Intervention: 0.06% ISV-205
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 0.1% ISV-205
Number of subjects: 136

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 136
Study: 11096144

Group type: EXPERIMENTAL
Intervention: Low protein diet
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Higher protein diet
Number of subjects: 1494
Study: 8889855

Group type: EXPERIMENTAL
Intervention: High calcium intake (greater than 1000 mg/day) with physical activity
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Mean calcium intake less than 1000 mg/day with physical activity
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Calcium intake modifying effect on BMD among exercise groups
Number of subjects: 17
Study: 1294894

Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Buspirone (15 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 3882308

Group type: EXPERIMENTAL
Intervention: Ibuprofen 8 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibuprofen 12 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibuprofen 14 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibuprofen (all doses except 0 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 40
Study: 30740297

Group type: EXPERIMENTAL
Intervention: Denosumab (DB group; 120 mg per 4 weeks plus an additional 120 mg on days 8 and 15; n=125)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Zoledronic acid (ZA group; 4 mg per 4 weeks; n=125)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Denosumab (DB group)
Number of subjects: 250
Study: 29713250

Group type: EXPERIMENTAL
Intervention: β-alanine (BA) supplementation
Number of subjects: 30
Study: 26869181

Group type: EXPERIMENTAL
Intervention: Enhanced model of early infant primary care with targeted support and care coordination for Aboriginal families, starting during the antenatal period or after birth.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced model of early infant primary care
Number of subjects: 0
Study: 25070824

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV) applied during a 2-hour spontaneous breathing trial (SBT-2)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Noninvasive positive pressure ventilation (NPPV) applied during pulmonary infection control (PIC) window
Number of subjects: 102
Study: 23000471

Group type: EXPERIMENTAL
Intervention: Chemical activation with 10 s waiting interval (ECB)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chemical activation with 30 s waiting interval (CDB)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chemical activation with 0 s waiting interval (UNB)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chemical activation with 0 s waiting interval (BTB)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Light activation of all adhesives
Number of subjects: 48
Study: 20236990

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) delivered by trained nurses in three individual appointments
Number of subjects: 117

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 117
Study: 19388288

Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated ventricular catheter (Group A)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Plain ventricular catheters with prophylactic dual antibiotics (Group B)
Number of subjects: 110
Study: 16255448

Group type: EXPERIMENTAL
Intervention: Group 1 (instruction burden) - instructions to complete the supplementary questionnaire if certain questions in the primary questionnaire were answered.
Number of subjects: 4494

Group type: COMPARATOR
Intervention: Group 2 (response burden) - instructions to complete both questionnaires irrespective of answers to the primary questionnaire.
Number of subjects: 4494
Study: 12413994

Group type: EXPERIMENTAL
Intervention: Highly purified urinary FSH
Number of subjects: 267

Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 267
Study: 9440384

Group type: EXPERIMENTAL
Intervention: Traditional yogurt (125 g/d for 1 month)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Milk fermented with yogurt cultures and Lactobacillus casei (YC) (125 g/d for 1 month)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nonfermented gelled milk (125 g/d for 1 month)
Number of subjects: 39
Study: 7602342

Group type: EXPERIMENTAL
Intervention: Doxorubicin 75 mg/m2 (arm A)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: CYVADIC (cyclophosphamide, vincristine, doxorubicin, and dacarbazine) (arm B)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Ifosfamide 5 g/m2 plus doxorubicin 50 mg/m2 (arm C)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Comparison among all arms
Number of subjects: 663
Study: 2196207

Group type: EXPERIMENTAL
Intervention: Heat probe thermocoagulation
Number of subjects: 137
Study: 345561

Group type: EXPERIMENTAL
Intervention: Anti-human thymocyte globulin (ATG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Steroids (control group)
Number of subjects: 0
Study: 31843638

Group type: EXPERIMENTAL
Intervention: FPNG Plus (substance use prevention and healthy nutrition)
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: FPNG (substance use prevention only)
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Comparison condition (focusing on academic success)
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Random subsample of 126 dyads (42 from each program)
Number of subjects: 1494
Study: 29624549

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted transanal total mesorectal excision
Number of subjects: 49
Study: 27804862

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 25751578

Group type: EXPERIMENTAL
Intervention: Losmapimod, 7.5 mg bid orally
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Losmapimod
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 24139191

Group type: EXPERIMENTAL
Intervention: BELIEF: Birth Emotions - Looking to Improve Expectant Fear (midwife-led psycho-education intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 22009228

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 3
Study: 18439088

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Total fatty acids (FAs)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFAs)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Ratios of SFAs/n‐3 PUFAs
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Ratios of SFAs/n‐3 HUFAs
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: n‐6 PUFAs/n‐3 PUFAs
Number of subjects: 203
Study: 17452162

Group type: EXPERIMENTAL
Intervention: Amiodarone (n = 837)
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Amiodarone (n = 696) at doses >2.0 mg/kg
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Amiodarone (n = 559) at doses >3.0 mg/kg
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Amiodarone (n = 219) at doses >4.0 mg/kg
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Amiodarone (n = 837) with a mean daily dose of 3.7 mg/kg (300 mg)
Number of subjects: 1669

Group type: COMPARATOR
Intervention: Placebo (n = 832)
Number of subjects: 1669
Study: 14620524

Group type: EXPERIMENTAL
Intervention: New paracetamol formulation with sodium bicarbonate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional paracetamol formulation
Number of subjects: 12
Study: 10632650

Group type: EXPERIMENTAL
Intervention: Bismuth-based quadruple therapy (two single triple capsules containing 60 mg of bismuth subcitrate, 125 mg of tetracycline, and 125 mg of metronidazole) plus lansoprazole 30 mg b.d. for 7 days
Number of subjects: 66
Study: 8938547

Group type: EXPERIMENTAL
Intervention: Growth hormone (single subcutaneous dose)
Number of subjects: 40
Study: 1384949

Group type: EXPERIMENTAL
Intervention: MOPP
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MOPP alternating with ABVD
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Infertility and lower income (1 year before diagnosis)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Survivors' reports of problems attributed to cancer
Number of subjects: 93
Study: 3868934

Group type: EXPERIMENTAL
Intervention: 4'-epi-adriamycin (EPI) 50 mg/day for 6 days (regimen A)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 4'-epi-adriamycin (EPI) 60 mg/day for 3 days X 2 courses with 4 days interval (regimen B)
Number of subjects: 37
Study: 29727043

Group type: EXPERIMENTAL
Intervention: Recombinant Escherichia coli‐asparaginase (rASNase)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Native E.coli asparaginase (Asparaginase medac)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 199
Study: 27827284

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 23
Study: 24928586

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 262
Study: 23206463

Group type: EXPERIMENTAL
Intervention: Combined general/epidural anaesthesia
Number of subjects: 61

Group type: COMPARATOR
Intervention: General anaesthesia alone (control group)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study: 20591171

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR) intervention using a combination of three videotaped visits and five telephone calls, an in-home messaging device, and additional telephonic contact as needed over a 3-month study period
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 50
Study: 17570803

Group type: EXPERIMENTAL
Intervention: Eighth grade level message
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Ninth grade level message
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: First year college level message
Number of subjects: 519
Study: 16340286

Group type: EXPERIMENTAL
Intervention: Bilateral tonsillectomy
Number of subjects: 197

Group type: COMPARATOR
Intervention: Unilateral tonsillectomy
Number of subjects: 197
Study: 12632661

Group type: EXPERIMENTAL
Intervention: Patients with COPD
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy blood donors (control group)
Number of subjects: 46
Study: 10337455

Group type: EXPERIMENTAL
Intervention: Myrtol standardized (MYS, Gelomyrtol forte, 3 x 300 mg)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Myrtol standardized (MYS)
Number of subjects: 246
Study: 7789631

Group type: EXPERIMENTAL
Intervention: doxazosin
Number of subjects: 30

Group type: COMPARATOR
Intervention: captopril
Number of subjects: 30

Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 30
Study: 1819779

Group type: EXPERIMENTAL
Intervention: Intramuscular beta-interferon (3 x 10(6) IU for 10 consecutive days)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo intramuscular injections
Number of subjects: 94
Study: 7146040

Group type: EXPERIMENTAL
Intervention: Controlled-release preparation of ferrous glycine sulphate ('Ferrocontin' Continus)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ferrous fumarate
Number of subjects: 40
Study: 30117784

Group type: EXPERIMENTAL
Intervention: Tailored ACT mobile app (n=17)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-tailored ACT mobile app (n=22)
Number of subjects: 39
Study: 28743662

Group type: EXPERIMENTAL
Intervention: End-of-life conversation card game
Number of subjects: 93
Study: 26090580

Group type: EXPERIMENTAL
Intervention: Yoga Intervention (YI)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Aerobic Dance Control (DC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 76
Study: 25028457

Group type: EXPERIMENTAL
Intervention: Finasteride (7-year randomized, double-blind, placebo-controlled trial)
Number of subjects: 13590

Group type: EXPERIMENTAL
Intervention: Larger sites and/or sites that received retention and adherence grants
Number of subjects: 13590
Study: 20882342

Group type: EXPERIMENTAL
Intervention: 2.5% Jatropha curcas seed meal (JCSM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5% Jatropha curcas seed meal (JCSM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 7.5% Jatropha curcas seed meal (JCSM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10% Jatropha curcas seed meal (JCSM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (soya bean meal 20%)
Number of subjects: 30
Study: 19412944

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000000
Study: 17470864

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg IV every 2 weeks and erlotinib 150 mg orally daily
Number of subjects: 51
Study: 15370671

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 180

Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Early discontinuation of antibiotic therapy in FUO patients
Number of subjects: 180
Study: 11358776

Group type: EXPERIMENTAL
Intervention: What Should I Do? booklet
Number of subjects: 4878

Group type: EXPERIMENTAL
Intervention: Health Care Manual booklet
Number of subjects: 4878

Group type: COMPARATOR
Intervention: Control group (no booklet)
Number of subjects: 4878
Study: 7836016

Group type: EXPERIMENTAL
Intervention: HIV seropositive group
Number of subjects: 40000

Group type: COMPARATOR
Intervention: HIV seronegative group
Number of subjects: 40000
Study: 3221960

Group type: EXPERIMENTAL
Intervention: Radiotherapy with 60Co teletherapy in doses of 60 Gy (30 fr) for 6 weeks
Number of subjects: 139

Group type: COMPARATOR
Intervention: Radiotherapy with 60Co teletherapy in doses of 60 Gy (30 fr) for 6 weeks + CCNU in one dose of 100 mg/m repeated at intervals of 6‐8 weeks
Number of subjects: 139
Study: 29068044

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced sonothrombolysis (CEST)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sham CEST
Number of subjects: 83
Study: 26936093

Group type: EXPERIMENTAL
Intervention: High nCPAP at 7 cm of water
Number of subjects: 271

Group type: COMPARATOR
Intervention: Standard nCPAP at 5 cm of water
Number of subjects: 271
Study: 26432320

Group type: EXPERIMENTAL
Intervention: RPE/C (rapid palatal expansion and constriction) for 7 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: RPE (rapid palatal expansion) for 1 week
Number of subjects: 44
Study: 23601264

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (Group IVM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural morphine (Group EM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural morphine-bupivacaine (Group EMB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural morphine-ropivacaine (Group EMR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study: 21397260

Group type: EXPERIMENTAL
Intervention: Standard adverse event reporting system (period 1)
Number of subjects: 2

Group type: COMPARATOR
Intervention: New adverse event reporting system focusing on 6 sentinel events (period 2)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: New adverse event reporting system (period 2)
Number of subjects: 2
Study: 18300930

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) of the ankle dorsiflexors and quadriceps for 2 weeks of neuromuscular electrical stimulation followed by 8 weeks of FES used at home and school
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group continued with usual physiotherapy program
Number of subjects: 14
Study: 16511729

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study: 12662230

Group type: EXPERIMENTAL
Intervention: Same size dressing (SSD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double size dressing (DSD)
Number of subjects: 0
Study: 11152032

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with 1/400000 adrenaline (n=8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Plain bupivacaine 0.25% (n=7)
Number of subjects: 15